- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01326416
Evaluation of the Impact of Physical Reconditioning Associated With Specific Nutritional Supplementation in Obese Patients Suffering From Metabolic Syndrome (OBEFITT)
Evaluation of the Impact of Physical Reconditioning Associated With Specific Nutritional Supplementation in Obese Patients Suffering From Metabolic Syndrome. OBEFITT Study.
Android obesity contributes, via insulin resistance and endothelial dysfunction, to the development of cardiovascular atherosclerosis. It leads to poor quality of life. It is often associated with metabolic syndrome which includes, whatever the definitions used (National Education Cholesterol Program, NECP / Adult Treatment Panel III, ATP III or International Diabetes Federation, IDF), an increased waist measurement, an arterial high blood pressure and disorders of the glucide and lipid metabolism. The treatment of the current "epidemic" of obesity and metabolic syndrome in France (12.4 % of obese and 14 % of subjects with metabolic syndrome) thus requires new therapeutic approaches.
A well-balanced diet and a daily physical activity are the indispensable requirements for the treatment of obesity and metabolic syndrome. It is possible to associate it to pharmacological agents, but the results are often partial and transient. Preliminary data suggest that leucine or arginine supplementation could facilitate the loss of fat mass. Moreover, the physical exercise has also demonstrated benefits.
Sessions of physical reconditioning (aerobic work + muscular intensification) associated with a program of specific nutritional supplementation by a mixture of Leucine and Arginine (in the daytime) could improve the treatment of obese subjects affected by metabolic syndrome.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Rouen, France, 76031
- University Hospital of Rouen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Suffering from obesity (Body Mass Index (BMI) > 30kg.m-2) with a maximal weight of 135 kg
- Suffering from metabolic syndrome (International Federation of Diabetes(FID) definition)
- Hospitalized or followed in consultation
- Age 18 to 55 years old
- Not having recently participated in other clinical studies during the last days before pre-inclusion consultation
- Affiliated to a National Insurance scheme
- Having National Social Security insurance
Exclusion Criteria:
- Asthma, chronic respiratory failure, obstructive chronic bronchitis
- Current or recent Pneumothorax, recent pleural draining or biopsy, current hemoptysis, untreated / in course of treatment active tuberculosis
- Coronaropathy, myocardiopathy, myocarditis, unstable cardiac failure, ventricular rhythm disorders
- Severe Anemia
- Severe inferior members Arteritis
- Incapacity to walk or cycle
- Severe renal failure (Creatinine Clearance <or = 30 mL/min)
- Severe Sepsis
- Psychiatric Disorders (Diagnostic and Statistical Manual - Revision 4 (DSM IV) criteria) such as schizophrenia, other psychoses or major depressive non treated syndromes
- Severe or non treated Eating Disorders implicated in obesity (compulsive access, bulimia)
- Patients under guardianship or with curators
- Women in age of procreation without means of effective contraception
- Pregnant or breast-feeding women
- Taking medicates such as: proteinate powder (Protifar ®, SP95 ®, Orlistat (Xenical ®, Ally ®), exenatide (Byetta ®), sitagliptin (Januvia ®, Xelevia ®), vildagliptin (Galvus ®), sitagliptin-metformin (Janumet ®), Vildagliptin-metformin (Eucreas ®), tadalafil (Cialis ®) sildenafil (Viagra ®)
- Drug addiction to opiates in the last six months
- Alcohol or drug abuse
- Infection by Human Immunodeficiency Virus (HIV) , viral hepatitis B and viral hepatitis C
- Active addiction to smoking in more than 8 cigarettes a day
- Understanding badly spoken or written French
- Performed, in 2 to 3 days preceding the Dual-energy X-Ray Absorptiometry (DEXA) exam, of a bone scintigraphy or a digestive tract radiological examination with the use of barium type of contrast agent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: S: Nutritional Supplementation alone
Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g of L-Leucine and 9 g of L-arginine), to distribute during each of the 3 main meals.
|
Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
|
|
Active Comparator: A: Physical Reconditioning alone
Physical reconditioning sessions led by a trainer three times a week for 6 months.
|
Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life.
The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
|
|
Active Comparator: AS: Physical Reconditioning + Nutritional Supplementation
Association for six months of a specific nutritional supplementation by 21 g of L-Leucine and 9 g of L-arginine per day (to distribute during each of the 3 main meals) and of physical reconditioning sessions three times a week.
|
|
|
No Intervention: C: Lifestyle counseling
Usual advice given in consultation on the need for a balanced diet and regular physical activity
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total body fat mass
Time Frame: 6 months
|
Change in total body fat mass estimated by Dual-energy X-Ray Absorptiometry (DEXA).
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight
Time Frame: 6 months
|
Change in weight, visceral fat mass, total lean mass, Bone Mineral Density, clinical and biological parameters of metabolic syndrome, insulin resistance, vascular inflammation parameters, heart rate variability, quadriceps strength, ventilatory parameters and quality of life score.
|
6 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vanessa FOLOPE, M.D., University Hospital, Rouen
Publications and helpful links
General Publications
- Folope V,Meret C,Castres I,Tourny C,Houivet E,Grigioni S,Lelandais H,Petit A,Coquard A,Guérin C,Quillard M,Bôle-Feysot C,Déchelotte P,Achamrah N,Coëffier M
- Évaluation de l'effet d'un programme d'activité physique adaptée associé à une supplémentation en Leucine et en Arginine chez des sujets obèses présentant un syndrome métabolique : Protocole OBEFITT - 2018 - V. Folope Leborgne 1, ⁎ , C. Meret 1, E. Houivet 2, N. Achamrah 1, S. Grigioni 1, A. Rimbert 1, A. Petit 1, M. Coeffier 1, P. Déchelotte 1
- Debeaumont D, Tardif C, Folope V, Castres I, Lemaitre F, Tourny C, Dechelotte P, Thill C, Darmon A, Coquart JB. A specific prediction equation is necessary to estimate peak oxygen uptake in obese patients with metabolic syndrome. J Endocrinol Invest. 2016 Jun;39(6):635-42. doi: 10.1007/s40618-015-0411-7. Epub 2015 Dec 22.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nutrition Disorders
- Metabolic Diseases
- Overnutrition
- Body Weight
- Glucose Metabolism Disorders
- Insulin Resistance
- Hyperinsulinism
- Overweight
- Pathological Conditions, Signs and Symptoms
- Behavior
- Nutritional and Metabolic Diseases
- Signs and Symptoms
- Obesity
- Metabolic Syndrome
- Motor Activity
- Amino Acids, Peptides, and Proteins
- Amino Acids
- Amino Acids, Basic
- Amino Acids, Diamino
- Amino Acids, Essential
- Amino Acids, Branched-Chain
- Arginine
- Leucine
Other Study ID Numbers
- 2008/066/HP
- 2009-009155-37 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical ConditionsUnited States
-
Central Hospital, Nancy, FranceNot yet recruiting
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsCompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Dr. Christopher McGowanRecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation TechniquesUnited States
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
Clinical Trials on L-Leucine and L-arginine
-
Juliano CasonattoUnknown
-
Emory UniversityNational Institute of Mental Health (NIMH)Recruiting
-
Emory UniversityNational Center for Complementary and Integrative Health (NCCIH); Children's...CompletedSickle Cell Disease | Vaso-occlusive Pain EpisodeUnited States
-
Instituto de Oncología Ángel H. RoffoCompletedUnresectable Multiple Brain Metastases
-
Hospital Civil de GuadalajaraNot yet recruitingArginine + Citrulline as a Supplement for Weight Gain in Fetus With a Decrease in Their Growth CurveFetal Growth Retardation
-
University Hospital, Strasbourg, FranceCompletedSkeletal Muscle Ischemia | Severe Lower Limb Ischemia | Mitochondrial DysfunctionFrance
-
Northwell HealthCompletedPure Red Cell Aplasia | Diamond Blackfan Anemia | Blackfan Diamond Syndrome | DBA | Congenital Hypoplastic AnemiaUnited States
-
Gdansk University of Physical Education and SportMedical University of GdanskCompleted
-
Columbia UniversityCompleted
-
IntraBio IncNot yet recruitingSpinocerebellar Ataxia Type 6 | Episodic Ataxia Type 2 | CACNA1A | Familial Hemiplegic Migraine-1United States, Germany, Italy, Austria, Greece, Switzerland, United Kingdom